
|Videos|August 19, 2022
Second-Line Treatment Approaches for R/R DLBCL
Author(s)Ian Flinn, MD, PhD
An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5




















